ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time.

The webinar will feature a presentation from KOL and discoverer of the vitamin activity of NR, Dr. Charles Brenner, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and ChromaDex Chief Scientific Advisor, who will discuss the latest research on NR and its many benefits as a precursor to nicotinamide adenine dinucleotide (NAD⁺). NAD⁺ is the central catalyst to multiple metabolic processes and a critical ally to cellular resilience and repair in healthy aging.

ChromaDex’s consumer supplement, Tru Niagen®, which features the company’s proprietary ingredient Niagen®, patented NR, will be discussed as the market’s most scientifically supported way to boost NAD⁺. Additionally, ChromaDex’s President & CEO, Rob Fried, will provide a company update.

A live question and answer session will follow. The event is open to the public and to register, please click here.

About Dr. Charles Brenner:

Dr. Charles Brenner, is one of the world’s leading experts on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, and the discoverer of the vitamin activity of nicotinamide riboside (NR). Dr. Brenner is a 1983 graduate of Wesleyan University who worked for five years in industry (Chiron Corporation and DNAX Research Institute) prior to earning his 1993 PhD in Cancer Biology in the Biochemistry Department of Stanford University. He then served as a Leukemia Society of America Fellow at Brandeis University. Dr. Brenner has been an independent and externally funded investigator for 26 years, having served on the faculty of Thomas Jefferson University (1996-2003), Dartmouth College (2003-2009), University of Iowa (2009-2020), where he was the Roy J. Carver Chair and Head of the Biochemistry Department and the Beckman Research Institute of City of Hope (2020-present), where he is the inaugural Alfred E. Mann Chair of the Department of Diabetes & Cancer Metabolism. Brenner has won numerous awards for his research including new investigator awards from the March of Dimes, the Burroughs Wellcome Trust, the Arnold & Mabel Beckman Foundation, research awards from the NIH, the NSF, Lung Cancer Research Foundation and the Gates Foundation, and prestigious lectureships or honors from the University of Michigan, Brown University, University of Nebraska, the Spanish National Cancer Institute, the American Society for Biochemistry and Molecular Biology and the American Society of Nutrition. His work on NR was licensed and developed into the Tru Niagen consumer product by ChromaDex, a company for which he serves as the chief scientific advisor. He is globally in demand to educate people about NAD, having lectured all over North and Central America, Europe, the Middle East, the Far East and Oceana. His laboratory continues to work on unsolved problems in metabolism as they relate to virology, women’s and children’s health, cancer, chronic and degenerative conditions, and rare diseases. When he is not doing science or teaching about NAD, he can be found exercising or gardening in Pasadena, California.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether Niagen® is the market’s most scientifically supported way to boost NAD⁺ and whether NAD is the central catalyst to multiple metabolic processes and a critical ally to cellular resilience and repair in healthy aging. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.